Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET
Company Participants
Paul Goodson – Investor Relations
Wenbin Jiang – Chief Executive Officer
William McCombe – Chief Financial Officer
Conference Call Participants
Tejas Savant – Morgan Stanley
Brendan Smith – TD Cowen
Mason Carrico – Stephens
John Barnidge – Piper Sandler
Andrew Cooper – Raymond James
Operator
Thank you for standing by. At this time, I’d like to welcome everyone to the Cytek Biosciences’ Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions] I will now turn the conference over to Paul Goodson, Investor Relations. Please go ahead.
Paul Goodson
Thank you, operator, earlier today, Cytek Biosciences released financial results for the quarter ended September 30, 2024. If you haven’t received this news release, or if you’d like to be added to the company’s distribution list, please send an email to investors@cytekbio.com.
Joining me today from Cytek are Wenbin Jiang CEO and CFO Bill McCombe. Before we begin, I’d like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek’s business plans, strategies, opportunities and financial projections.
These statements are based on the company’s current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in this press release Cytek issued today and in Cytek’s filings with the SEC.
This call will include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles. Reconciliation to the